Physician

Bassam I Mattar, MD

According to 2025 Medicare claims, Bassam Mattar, MD (NPI: 1053372649) practices hematology/oncology in the Wichita, KS market, with the plurality of this provider's patient population coming from Sedgwick, KS. This provider's primary affiliated billing organization is CANCER CENTER OF KANSAS, P.A. (NPI: 1841251394; TIN: 481181579) and primary practice location at 67114-8778. Mattar is affiliated with the Aledade 38 KS CHC MSSP Enhanced (ACO ID: A4546), Aledade 155 National MSSP (ACO ID: A5358), and Vytalize Health KS 25 LLC (ACO ID: A5671), participating under the MSSP model.

Mattar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,637 traditional Medicare patients, billed 740,012 HCPCS/CPT codes, and received $13,800,548 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,780 prescription claims across 534 beneficiaries totaling $5,621,627 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 32 claims. Open Payments data shows 236 records totaling $148,776. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $4,255,527 to $13,800,548. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,633,414 to $5,621,627. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,391	285,954	$4,255,527
2016	1,410	502,408	$5,511,137
2017	1,448	499,778	$5,826,610
2018	1,528	461,093	$6,858,240
2019	1,545	462,499	$6,683,267
2020	1,508	761,439	$9,576,329
2021	1,374	671,180	$7,810,619
2022	1,432	684,309	$9,198,393
2023	1,543	656,034	$10,284,753
2024	1,637	740,012	$13,800,548

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	383	3,201	$1,633,414
2016	409	2,981	$1,830,203
2017	404	3,190	$2,124,197
2018	448	3,336	$2,528,774
2019	418	3,193	$2,710,962
2020	476	3,307	$2,814,311
2021	497	3,179	$3,649,073
2022	490	3,096	$4,497,270
2023	476	2,884	$3,641,067
2024	534	3,780	$5,621,627

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	94	398	$33,025
2016	51	116	$10,274
2017	N/R	N/R	N/R
2018	13	13	$1,318
2019	N/R	47	$2,408
2020	14	95	$7,353
2021	14	83	$5,301
2022	16	63	$3,981
2023	12	25	$2,321
2024	16	32	$3,297

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	860	2,085	$88
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	752	1,528	$12
36415	Insertion of needle into vein for collection of blood sample	618	3,901	$9
85027	Complete blood cell count (red cells, white blood cell, platelets), automated test	613	3,732	$6
85007	Microscopic examination for white blood cells with manual cell count	612	3,731	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	114	2,968	$1,541,922
Pomalyst	Pomalidomide	22	616	$511,780
Kisqali	Ribociclib Succinate	34	917	$509,358
Venclexta	Venetoclax	40	1,182	$343,237
Mekinist	Trametinib Dimethyl Sulfoxide	21	630	$340,359

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	16	18	$2,533
J8700	Temozolomide, oral, 5 mg	N	N/R	14	$764

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	228	$56,545	Takeda Pharmaceuticals U.S.A., Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	8	$92,231	ABBVIE INC.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Bassam I. Mattar, MD?

Tedicare shows public-source Medicare data for Bassam I. Mattar, MD (NPI 1053372649), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Bassam I. Mattar, MD have ACO affiliation data?

Bassam I. Mattar, MD is shown with ACO affiliation data for Aledade 38 KS CHC MSSP Enhanced (MSSP, ACO ID A4546), Aledade 155 National MSSP (MSSP, ACO ID A5358), and Vytalize Health KS 25 LLC (MSSP, ACO ID A5671).

What billing organization is linked to Bassam I. Mattar, MD?

Bassam I. Mattar, MD is linked to CANCER CENTER OF KANSAS, P.A. (billing NPI 1841251394) in the available physician profile data.

Does Bassam I. Mattar, MD have Open Payments data?

Bassam I. Mattar, MD has 236 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.